|
Gene: BEX2 |
Gene summary for BEX2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | BEX2 | Gene ID | 84707 |
Gene name | brain expressed X-linked 2 | |
Gene Alias | BEX1 | |
Cytomap | Xq22.2 | |
Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | Q9BXY8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84707 | BEX2 | LZE4T | Human | Esophagus | ESCC | 1.35e-05 | -1.62e-02 | 0.0811 |
84707 | BEX2 | LZE7T | Human | Esophagus | ESCC | 1.42e-09 | 1.24e+00 | 0.0667 |
84707 | BEX2 | LZE8T | Human | Esophagus | ESCC | 1.13e-03 | 2.88e-01 | 0.067 |
84707 | BEX2 | LZE22T | Human | Esophagus | ESCC | 9.23e-04 | 1.44e-01 | 0.068 |
84707 | BEX2 | LZE24T | Human | Esophagus | ESCC | 2.81e-26 | 1.18e+00 | 0.0596 |
84707 | BEX2 | P1T-E | Human | Esophagus | ESCC | 2.97e-07 | 9.85e-01 | 0.0875 |
84707 | BEX2 | P2T-E | Human | Esophagus | ESCC | 5.32e-30 | 7.14e-01 | 0.1177 |
84707 | BEX2 | P4T-E | Human | Esophagus | ESCC | 1.54e-27 | 1.02e+00 | 0.1323 |
84707 | BEX2 | P5T-E | Human | Esophagus | ESCC | 3.11e-22 | 6.08e-01 | 0.1327 |
84707 | BEX2 | P8T-E | Human | Esophagus | ESCC | 2.34e-62 | 1.43e+00 | 0.0889 |
84707 | BEX2 | P10T-E | Human | Esophagus | ESCC | 7.78e-74 | 1.57e+00 | 0.116 |
84707 | BEX2 | P12T-E | Human | Esophagus | ESCC | 3.21e-26 | 5.71e-01 | 0.1122 |
84707 | BEX2 | P15T-E | Human | Esophagus | ESCC | 1.26e-20 | 7.81e-01 | 0.1149 |
84707 | BEX2 | P16T-E | Human | Esophagus | ESCC | 1.57e-19 | 5.72e-01 | 0.1153 |
84707 | BEX2 | P22T-E | Human | Esophagus | ESCC | 2.27e-60 | 1.28e+00 | 0.1236 |
84707 | BEX2 | P23T-E | Human | Esophagus | ESCC | 3.56e-16 | 1.20e+00 | 0.108 |
84707 | BEX2 | P24T-E | Human | Esophagus | ESCC | 4.29e-08 | 7.76e-03 | 0.1287 |
84707 | BEX2 | P26T-E | Human | Esophagus | ESCC | 9.18e-47 | 9.58e-01 | 0.1276 |
84707 | BEX2 | P27T-E | Human | Esophagus | ESCC | 6.80e-12 | 2.81e-01 | 0.1055 |
84707 | BEX2 | P28T-E | Human | Esophagus | ESCC | 1.27e-11 | 2.98e-01 | 0.1149 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | |
Stomach | SIM | |
Liver | NAFLD | |
Liver | Cirrhotic | |
Liver | HCC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BEX2 | SNV | Missense_Mutation | c.356N>A | p.Arg119Lys | p.R119K | Q9BXY8 | protein_coding | tolerated(0.17) | benign(0.026) | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
BEX2 | SNV | Missense_Mutation | c.124N>C | p.Asn42His | p.N42H | Q9BXY8 | protein_coding | deleterious(0) | possibly_damaging(0.66) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
BEX2 | insertion | Frame_Shift_Ins | novel | c.171_172insACGGGAAGACAATTGGGGTTAAGTGTCCCAGCAGAACTAGG | p.Glu58ThrfsTer30 | p.E58Tfs*30 | Q9BXY8 | protein_coding | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
BEX2 | SNV | Missense_Mutation | novel | c.130N>T | p.Leu44Phe | p.L44F | Q9BXY8 | protein_coding | tolerated(0.08) | possibly_damaging(0.525) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BEX2 | SNV | Missense_Mutation | novel | c.395N>T | p.Arg132Met | p.R132M | Q9BXY8 | protein_coding | deleterious(0) | possibly_damaging(0.799) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
BEX2 | SNV | Missense_Mutation | novel | c.55N>A | p.Glu19Lys | p.E19K | Q9BXY8 | protein_coding | tolerated_low_confidence(0.31) | benign(0.007) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
BEX2 | SNV | Missense_Mutation | c.215C>A | p.Pro72His | p.P72H | Q9BXY8 | protein_coding | tolerated(0.1) | benign(0.031) | TCGA-AP-A0LT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
BEX2 | SNV | Missense_Mutation | novel | c.69G>T | p.Glu23Asp | p.E23D | Q9BXY8 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BEX2 | SNV | Missense_Mutation | c.184G>T | p.Val62Phe | p.V62F | Q9BXY8 | protein_coding | tolerated(0.15) | benign(0.027) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
BEX2 | SNV | Missense_Mutation | novel | c.97A>T | p.Met33Leu | p.M33L | Q9BXY8 | protein_coding | deleterious(0.04) | possibly_damaging(0.743) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |